Cardioprotective medication use is an important secondary preventive treatment after cardiovascular events. Patients with schizophrenia have excess cardiovascular morbidity and mortality, but no studies have investigated whether taking recommended cardioprotective medication can reduce this excess mortality.
C ardiovascular disease, including ischemic heart disease and stroke, is the leading cause of death worldwide. 1 Deaths from cardiovascular disease have decreased during the past decades, especially in Western Europe, North America, and Japan. 2 This decrease in cardiovascular death is believed to be a result of multiple factors, including improvement in lifestyle behavior (eg, smoking cessation, physical activity, and balanced diet), implementation of interventional cardiologic procedures (eg, coronary artery bypass grafting and percutaneous coronary intervention [PCI] ), and increases in prophylactic cardiovascular treatment (antithrombotics, β-blockers, angiotensinconverting enzyme inhibitors [ACEIs] , and statins). 3 Patients with schizophrenia have an excess cardiac mortality, which contributes to a shortened life expectancy of 15 to 20 years compared with the general population. 4, 5 Studies 6,7 on survival after ischemic heart disease have reported worse outcomes in patients with schizophrenia compared with people without mental illness. The causes of the differences in outcome are unclear, although earlier findings suggest deficits in quality of medical care and fewer cardiac interventions performed in patients with schizophrenia compared with the general population. [8] [9] [10] Recent studies 6, 11 indicate that patients with schizophrenia who receive cardiac revascularization procedures have poorer outcome after ischemic heart disease, and a recent Danish population-based study 11 found that patients with severe mental illness (SMI) are less likely to receive recommended, long-term, secondary preventive medications after PCI; this finding is further supported by a study 12 that found no differences in short-term mortality but an increased long-term mortality rate after ischemic heart disease in patients with schizophrenia compared with the general population.
Taking recommended cardioprotective medication after myocardial infarction (MI) reduces hospital admissions, 13 health care costs, and all-cause mortality in patients without psychiatric conditions. 14 Studies 11, 15 on the prescription rate of cardioprotective medication in patients with SMI have been limited, and no studies have examined the association of prophylactic cardiac treatment exposure with mortality rates after MI in patients with schizophrenia compared with the rates in the general population.
In the current study, we investigated the association of secondary preventive cardiovascular treatment with all-cause mortality after MI in patients with schizophrenia compared with those without schizophrenia using the Danish nationwide health care registries. 17 The remaining patients with MI from the cohort served as controls representing patients with MI in the general population. Incident cases of schizophrenia after MI diagnosis in the control cohort were excluded from the analyses. We excluded patients younger than 30 years who had an MI to minimize inclusion of patients with potential congenital heart defects.
Methods

Study Population
Drug Exposure
From the NPR, we identified all dispensed prescriptions for guideline-recommended secondary preventive treatments after MI using the Anatomical Therapeutic Chemical (ATC) code in agreement with the World Health Organization. 18 Data on every dispensed prescription, including dispensing date, defined daily dose, and the total amount of pills dispensed, are available from January 1, 1995, in the NPR for the entire Danish population.
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We defined 5 therapeutic drug groups: antiplatelets (ATC code B01AC), vitamin K antagonists (ATC codes B01AA, B01AE, and B01AF), β-blockers (ATC code C07), ACEIs (ATC code C09), and statins (ATC codes C10). Because of the natural progress of change in treatment regimens during follow-up, we allowed patients to switch among therapeutic groups at any time.
The treatment exposure groups were created as time-varying covariates. We assumed the use of 1 defined daily dose per day with a grace period of 14 days. The grace period was introduced to allow for some degree of nonadherence and for irregular dispensing attributable to stockpiling. Periods of concomitant treatment were collapsed to coherent periods during the follow-up. For each individual, we defined exposed and unexposed periods
Key Points
Question Is use of cardioprotective medication after myocardial infarction associated with reduced mortality rates among patients with schizophrenia?
Findings In this Danish nationwide cohort study of 105 018 patients with myocardial infarction, patients with schizophrenia who were not exposed to cardioprotective medication had an excess mortality rate; however, exposure to medication was associated with a reduced mortality.
Meaning The increased cardiovascular mortality among patients with schizophreniawasreducedinthecurrentstudyifpatientswereefficiently administered cardioprotective treatment after cardiac events.
during the entire follow-up period, and these periods where used in the calculation of hazard ratios (HRs) for mortality estimates.
Monotherapy was defined as treatment periods with use of one of the previously described treatment groups. Dual therapy was defined as 2 overlapping periods of concurrent treatments, whereas triple therapy was defined as 3 or more overlapping treatment periods. Patients were allowed to switch groups at any time during the follow-up, according to the use of time-varying covariates in the Cox proportional hazards regression model.
Outcome Measures
The primary study outcome was time to all-cause mortality using time of medication exposure as a time-dependent covariate. Mortality data were retrieved from the Danish Causes of Death Register, which contains data on age of death and underlying cause of death. 20 The discharge date of the MI hospitalization was used as the index date. All individuals were followed up from the time of index until the time of death or until December 31, 2015, whichever came first. Patients were allowed to initiate and discontinue use of medications throughout follow-up and thus change exposure status during the study period. The secondary outcome was time to all-cause mortality, comparing exposure to monotherapy, dual therapy, and triple therapy in patients diagnosed or not diagnosed with schizophrenia.
Covariates
This study included the demographic covariates sex, age, and calendar year of the index date. The number of MI readmissions after index were divided into 0, 1, or 2 or more. Furthermore, we defined patients who had received PCI according to the Danish health care classification system codes KFNG02 and KFNG05.
Cardiovascular Risk Factors
Patients were defined as having diabetes if they had a registered ICD-8 diagnosis code of 249 or 250 or an ICD-10 diagnosis code of E10 to E14 (diabetes). In addition, patients who claimed prescriptions for glucose-lowering drugs (ATC code A10B or A10XA) or insulins (ATC code A10A) without a registered diagnosis in the NPR were also considered as having diabetes because patients treated by the general practitioner are not registered in the NPR. Patients who had a registered ICD-8 diagnosis code of 491 or 492, an ICD-10 diagnosis code of J41 to J44, or any prescription of drugs for chronic obstructive pulmonary disease (COPD) (ATC code R03) were considered to have COPD. We defined hypertension as an 
Statistical Analysis
Descriptive analysis of the study population's demographics and illness history was initially conducted. The frequency and distribution of patient characteristics were described by calculating means (SDs) for continuous variables and numbers (percentages) for categorical variables.
The primary analysis was a Cox proportional hazards regression model that evaluated all-cause mortality using drug exposure as defined previously as a time-varying covariate. We adjusted for sex, year of birth, age at MI, calendar year, and PCI in the first adjusted model and then further adjusted for substance abuse, diabetes, COPD, and hypertension in the second adjusted model. We calculated unadjusted and adjusted HRs and their 95% CIs by using treated patients from the general population as reference and compared these data with those of patients diagnosed with schizophrenia.
The secondary outcome was the association of each therapeutic class from the guideline-recommended secondary preventive treatments using a Cox proportional hazards regression model with specific therapy exposure as a time-varying covariate. We used triple therapy in patients from the general population as a reference because this protocol is currently recommended in the Danish guidelines of treatment after MI (depending on risk profile).
The assumption for linearity in the Cox proportional hazards regression was met in the primary and secondary analyses. The significance level was defined as 2-sided P < .05. Statistical analyses were performed with Stata statistical software, version 14 (StataCorp) at the Statistics Denmark server with remote access.
Sensitivity Analysis
We evaluated the role of prior exposure to any of those medications investigated because many patients might already have initiated the treatment before incident MI. Thus, we applied the primary analysis considering only patients who were naive to these medications at the time of MI and started the follow-up from 1996 (because we did not have data on prior medication use for patients included in 1995). In addition, we compared patients with schizophrenia with all others experiencing an MI excluding all with any previous psychiatric diagnosis (comparing patients diagnosed with schizophrenia with a group of psychiatrically healthy persons). 
Results
Population Characteristics
Drug Exposure and Mortality Rates After MI
A total of 307 patients with schizophrenia (44.9%) and 27 752 patients from the general population (26.6%) died after index (P < .001). Causes of death were equally distributed between groups, with 66.2% of all deaths being defined as cardiovascular deaths. Patients diagnosed with schizophrenia who did not receive cardioprotective treatment had the highest mortality rate (HR, 8.78; 95% CI, 4.37-17.64) compared with the general population treated, with treated patients diagnosed with schizophrenia having an increased HR of 1.97 (95% CI, 1.25-3.10). No difference was found in mortality rates between nonexposed patients from the general population (HR, 2.95; 95% CI, 2.62-3.32) and patients with schizophrenia exposed to treatment (HR, 1.97; 95% CI, 1.25-3.10) when adjusting for baseline characteristics ( Table 2 ).
The subanalysis of mortality rates for each cardioprotective treatment showed a generally increased mortality rate among patients diagnosed with schizophrenia who were treated compared with treated patients in the general population with the exception of antiplatelets and statins (Table 2) . Similarly, patients diagnosed with schizophrenia who were not exposed to cardioprotective treatment had increased rates of mortality compared with patients from the background population who were not exposed to cardioprotective treatment (Table 2) for both the unadjusted and adjusted models. Patients diagnosed with schizophrenia who were exposed to cardioprotective treatment did not have a lower mortality rate than nonexposed patients from the background population (Table 2 ). In the sensitivity analysis that included only patients who initiated treatment without any prior use (n = 87 355), we observed patterns similar to the findings in the main analysis.
Medication Therapy and Mortality Rates
In the adjusted model, we found that patients diagnosed with schizophrenia did not have an increased HR for all-cause mortality compared with patients from the general population who received triple therapy as cardioprotective treatment ( Table 3) . We furthermore conducted a post hoc sensitivity analysis to investigate a potential association of SMI in the comparison group. When comparing only patients diagnosed with schizophrenia with a comparison group in which all with a previous psychiatric diagnosis were excluded, we found similar results as in our main analysis.
Discussion
In this large, nationwide, retrospective cohort study of 105 018 patients with MI with a total follow-up of 796 435 person-years, we found that when patients with schizophrenia were exposed to cardioprotective treatment, the mortality rate was high compared with patients not exposed, using treatment-exposed patients from the general population as reference. By comparing the associations between different cardiac therapy strategies and mortality rates, we found that patients with schizophrenia who received any combination of triple therapy had the lowest mortality rates. Previous studies have found that patients with schizophrenia have increased cardiovascular mortality 5, 21 and a lower prescription rate for cardioprotective treatment 11,15 compared with the general population. The current study was the first, to our knowledge, to investigate the association between exposure to cardioprotective medication after MI and mortality rates among patients with schizophrenia compared with the general population. Mitchell Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; HR, hazard ratio. a Adjusted for sex, birth year, age at myocardial infarction, calendar year, and percutaneous coronary intervention.
b Adjusted for sex, birth year, age at myocardial infarction, calendar year, percutaneous coronary intervention, diabetes, chronic obstructive pulmonary disease, hypertension, and substance abuse. after MI among patients with SMI compared with the general population. These findings are similar to our finding of a lower use of antiplatelets, vitamin K antagonists, β-blockers, ACEIs, and statins in patients with schizophrenia compared with the general population. Nevertheless, studies from the United States have found that patients with schizophrenia were more adherent to statins than patients without psychiatric conditions, 22,23 although these studies were limited by the inclusion of patients who had at least 2 refills during a 12-month period in payer-provided care, which might have biased results toward an overrepresentation of well-functioning patients diagnosed with schizophrenia. A number of factors contribute to reduced medication adherence, including poor insight into physical illness, negative attitudes toward medication, or lack of understanding the purpose of the medications. 24 These contributing factors may be even worse in patients with schizophrenia, who have cognitive impairment, which has been linked to reduced medication adherence in general. 25 One study 26 found that adherence to hypoglycemic and antihypertensive medications was worse than adherence to antipsychotics in patients with schizophrenia. This explanation is further supported by earlier findings that suggest that patients with schizophrenia are less likely to consult their cardiologist after cardiac events. 27,28 Together, we believe that these results could point toward a deficit in establishing an appropriate cardiac treatment plan in patients with schizophrenia that causes failure in initiation and maintenance of cardioprotective treatment. This hypothesis could explain the results of a generally increased mortality rate among patients with schizophrenia, especially when the results suggest that these patients die of cardiovascular causes that might be treatable. The current data do not show causality as a result of the study design, and as such, more studies are needed to confirm the results. Prior observational studies 3, 29 have suggested that concomitant exposure to multiple cardioprotective medications results in lowered mortality rates compared with monotherapy or no treatment in people experiencing cardiovascular events. The results of the current study indicate a similar cardioprotective association with mortality rates in patients diagnosed with schizophrenia and the general population when exposed to multiple secondary preventive treatments. These findings are similar to those of the study by Korhonen et al, 3 who compared the association of multiple preventive therapies with mortality rates after MI in populations without psychiatric conditions and found a generally favorable association between triple therapy and mortality rates. According to European and US guidelines for the treatment of patients with MI, cardioprotective triple therapy should be considered in patients with high ischemic and bleeding risk.
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We do not have information on the specific risk variables in each patient or on any changes in treatment strategy provided by the cardiologists during follow-up. Therefore, the reason for persons not taking their medication may be their own initiative or their practitioner's recommendation. In our study, treatment with cardiac triple therapy was associated with reduced excess mortality rates among patients with schizophrenia, which could suggest a necessity of implementing and monitoring multiple secondary preventive cardiac treatments in patients with schizophrenia. The current findings might be explained by confounding by indication because patients with increased severity of MI might be more intensively treated with triple therapy, but the finding that all-cause mortality diminishes as treatment intensity increases may suggest that increased treatment intensity, despite increased cardiac risks, affects long-term outcome. The bias of increased cardiac risk associated with increased treatment intensity would be conservative and bias the results toward an increased mortality rate associated with an increased treatment intensity. On the other hand, more severely ill patients may have difficulties complying with planned treatment because of the complexity of taking multiple drugs, which could bias the results in the opposite direction. Given the increased cardiovascular risk among patients with schizophrenia, we believe that the current findings support the use of intensive cardioprotective treatments in patients with schizophrenia. In addition, these patients should be provided with accurate treatment that is closely monitored during follow-up, and treatment intensity should be increased after cardiac events in patients with schizophrenia in general because a diagnosis of schizophrenia may be associated with an increased cardiac risk, which potentially can be countered by secondary preventive cardiac treatment.
Limitations
There are several limitations that need to be addressed. First, treatment exposure was based on whether patients redeemed prescriptions; thus, we cannot be certain that the patients were actually taking the prescribed medication for the full amount of days that we calculated. However, we assume that when patients redeem prescriptions, they have the intention to take their medications. Second, we did not have information on the severity of MI (eg, left ventricular function and symptom status) or information on lifestyle factors, such as diet habits, physical activity, and smoking status; therefore, we were unable to adjust for these confounders in the regression models. Future research should attempt to assess the degree to which these factors contribute to the increased mortality in patients with schizophrenia. Despite adjusting for multiple confounders in the regression models, it is possible that some residual confounding may have occurred. We also did not have information on in-hospital medication, but because we included patients with MI from the general population in the main analyses, we expect that any bias would affect both populations equally. Third, we included patients across a broad period, and we are aware that treatment patterns and guideline recommendations for preventive cardiovascular assessment have changed significantly. However, we indirectly accounted for this difference by including patients without schizophrenia and adjusting to calendar year in the Cox proportional hazards regression model.
Conclusions
Our study suggests that patients with schizophrenia who are treated with cardioprotective treatment after MI have a lower mortality risk compared with patients who are not treated, similar to those treated in the general population. This finding suggests that some of the increased cardiac mortality among patients with schizophrenia can be reduced if these patients are efficiently administered secondary preventive treatment after cardiac events.
